PDCD1 and neoplasm: Immunotherapies mainly use monoclonal antibodies to stimulate an anti-tumor immune response directed against programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) or cytotoxic T lymphocyte antigen 4 (CTLA-4).